AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04814628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation
Description: All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop
Study NCT04814628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist
Description: All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Use of Test Product C in controlled use and ad libitum use sessions
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Use of Test Product D in controlled use and ad libitum use sessions
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product E
Description: Use of Test Product E in controlled use and ad libitum use sessions
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Product F: Subjects' OBMST
Description: Use of Reference Product F in controlled use and ad libitum use sessions. The subjects' Own Brand Moist Smokeless Tobacco (OBMST) reference products used in this study were commercially available and had been reported by the subjects as the brands they usually consume.
Study NCT06718101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection
Study NCT05461157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoperative silicone ointment
Description: The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
Study NCT05461157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative placebo ointment
Description: The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
Study NCT06718101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) Injection
Study NCT06720311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
Description: Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
Study NCT06720311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureterorenoscopy
Description: Flexible Ureterorenoscopy
Study NCT06720311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave Lithotripsy
Description: Shockwave Lithotripsy
Study NCT06719700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
Study NCT06719700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
Study NCT06719700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angio-immuno kinase inhibitor
Description: Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
Study NCT06719700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
Study NCT06719700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: PCI is recommended after the completion of chemoradiotherapy.
Study NCT06719700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Therapy with Toripalimab and Surufatinib
Description: Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
Study NCT06723639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A new two-layer surgical technique
Description: A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
Study NCT06723639 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard non-surgical treatment
Description: Standard non-surgical treatment
Study NCT06712147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Life's Hurdles: Mental health education
Description: The intervention group will cover educational topics around mental health including: mental health literacy, individual coping skills, stigma reduction strategies, resources for mental health support, and mental health rights.
Study NCT06712147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overcoming Life's Hurdles: Resources in the community
Description: The control group will cover topics including: mental health resources in the community, violence (i.e. domestic violence), employment and education opportunities, housing and tenant rights, immigration and acculturation, and community team building and empowerment.
Study NCT06740266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships in Primary Care (PFR-PC)
Description: Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting.
Study NCT06734884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 MG/ML [Fasenra]
Description: Subcutaneous injection 30 mg at day 2, week 4 and week 8.
Study NCT06734884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Description: Subcutaneous injection at day 2, week 4 and week 8
Study NCT06743295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction
Description: Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise.
Study NCT06738823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INTERVENTION GROUP : TRAINING WITH WIIFIT
Description: RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
Study NCT06738823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VESTIBULAR REHABILITATION TRAINING
Description: WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
Study NCT06739421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nCLE-NB-rEBUS-forcep biopsy
Description: The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
Study NCT06739421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nCLE-NB-rEBUS-TBCB
Description: The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
Study NCT06739421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-rEBUS-forcep biopsy
Description: The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
Study NCT06739421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-rEBUS-TBCB
Description: The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
Study NCT06739902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy Group
Description: Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.
Study NCT06739902 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VR + Traditional Physiotherapy Group
Description: Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
Study NCT06747546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: goal-directed treatment strategy based on oxygen supply and consumption balance
Description: The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3. A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing oxygen consumption (VO2) after CPB is compensated by increasing oxygen delivery (DO2) to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB.
Study NCT06747546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment group
Description: Ventilation support is adjusted to maintain arterial oxygen partial pressure and oxygen saturation. Appropriate fluid infusion to stabilize central venous pressure and ensure preload; Combined use of vasoactive drugs to maintain heart rate and blood pressure; Appropriate diuresis can improve urine output and reduce cardiac afterload. Blood transfusion is used to improve coagulation function and maintain appropriate hematocrit.
Study NCT06740825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose of 60 mg
Study NCT06740825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Twice daily (BID) dose of 400 mg on Days 1 through 32
Study NCT06747897 — intervention group
Intervention type: DEVICE
Intervention: MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)
Description: Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.
Study NCT06741969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab SC.
Study NCT06741969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC.
Study NCT06741969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Protocol-defined topical and systemic standard of care background treatments.
Study NCT06741969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care treatment
Description: Protocol-defined topical and systemic standard of care background treatments.
Study NCT06750471 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
Study NCT06750471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
Study NCT06737939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous ibuprofen
Description: A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.
Study NCT06737939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periprostatic nerve block
Description: A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
Study NCT06758739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin (Turmeric)
Description: Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.
Study NCT06758739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Steroid Injection
Description: Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
Study NCT06772974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxylamine Succinate USP
Description: Tab. Doxylamine Succinate
Study NCT06772974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger (zingiber officinale)
Study NCT06773234 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: DREEM Tool
Study NCT06772792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral administration
Study NCT06772792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral administration
Study NCT06771427 — intervention group
Intervention type: OTHER
Intervention: acupuncture GB20 or GB20 plus BL2
Description: acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.
Study NCT06771427 — intervention group
Intervention type: DRUG
Intervention: Chinese herbal tea TBDESJS
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
Study NCT06778447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Disc NP
Description: VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Study NCT06779539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225 mg oral once daily 12 weeks
Study NCT06773026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
Study NCT04982614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil ® 9
Description: GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months
Study NCT04982614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil ® 9
Description: GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months
Study NCT06083623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: single dose intramuscular injection
Study NCT06083623 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose intramuscular injection
Study NCT04872777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight
Description: Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days.
Study NCT06524882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivid Vision
Description: dichoptic video games played through a virtual reality headset
Study NCT06524882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia
Description: dichoptic movies/shows shown through a virtual reality headset
Study NCT06524882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Correction
Description: Glasses prescribed at investigator discretion
Study NCT05658029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARINA-1
Description: Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
Study NCT06535399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study NCT06781125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
Description: JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions.
Study NCT04749108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy - modified FOLFIRINOX regimen
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
Study NCT04749108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy - modified FOLFIRINOX regimen
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
Study NCT04749108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early tumor response evaluation by MRI volumetry
Description: Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.